370 related articles for article (PubMed ID: 23344907)
1. Delivery systems and local administration routes for therapeutic siRNA.
Vicentini FT; Borgheti-Cardoso LN; Depieri LV; de Macedo Mano D; Abelha TF; Petrilli R; Bentley MV
Pharm Res; 2013 Apr; 30(4):915-31. PubMed ID: 23344907
[TBL] [Abstract][Full Text] [Related]
2. Nonviral in vivo delivery of therapeutic small interfering RNAs.
Aigner A
Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
[TBL] [Abstract][Full Text] [Related]
3. Functional nanostructures for effective delivery of small interfering RNA therapeutics.
Hong CA; Nam YS
Theranostics; 2014; 4(12):1211-32. PubMed ID: 25285170
[TBL] [Abstract][Full Text] [Related]
4. A review of the current status of siRNA nanomedicines in the treatment of cancer.
Resnier P; Montier T; Mathieu V; Benoit JP; Passirani C
Biomaterials; 2013 Sep; 34(27):6429-43. PubMed ID: 23727262
[TBL] [Abstract][Full Text] [Related]
5. Non-viral siRNA delivery to the lung.
Thomas M; Lu JJ; Chen J; Klibanov AM
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):124-33. PubMed ID: 17459519
[TBL] [Abstract][Full Text] [Related]
6. siRNA delivery: from basics to therapeutic applications.
Musacchio T; Torchilin VP
Front Biosci (Landmark Ed); 2013 Jan; 18(1):58-79. PubMed ID: 23276909
[TBL] [Abstract][Full Text] [Related]
7. siRNA delivery systems for cancer treatment.
Oh YK; Park TG
Adv Drug Deliv Rev; 2009 Aug; 61(10):850-62. PubMed ID: 19422869
[TBL] [Abstract][Full Text] [Related]
8. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy.
Chen Y; Huang L
Expert Opin Drug Deliv; 2008 Dec; 5(12):1301-11. PubMed ID: 19040393
[TBL] [Abstract][Full Text] [Related]
9. Targeted delivery systems of small interfering RNA by systemic administration.
Kawakami S; Hashida M
Drug Metab Pharmacokinet; 2007 Jun; 22(3):142-51. PubMed ID: 17603214
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic face of RNAi: in vivo challenges.
Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
[TBL] [Abstract][Full Text] [Related]
11. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development.
Xie FY; Woodle MC; Lu PY
Drug Discov Today; 2006 Jan; 11(1-2):67-73. PubMed ID: 16478693
[TBL] [Abstract][Full Text] [Related]
12. Current Non-viral siRNA Delivery Systems as a Promising Treatment of Skin Diseases.
Rosa J; Suzuki I; Kravicz M; Caron A; Pupo AV; Praça FG; Bentley MVLB
Curr Pharm Des; 2018; 24(23):2644-2663. PubMed ID: 30084329
[TBL] [Abstract][Full Text] [Related]
13. Polycation-based nanoparticle delivery for improved RNA interference therapeutics.
Howard KA; Kjems J
Expert Opin Biol Ther; 2007 Dec; 7(12):1811-22. PubMed ID: 18034647
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle-based delivery system for application of siRNA in vivo.
Wang Y; Li Z; Han Y; Liang LH; Ji A
Curr Drug Metab; 2010 Feb; 11(2):182-96. PubMed ID: 20359287
[TBL] [Abstract][Full Text] [Related]
15. siRNAs: their potential as therapeutic agents--Part II. Methods of delivery.
Singh SK; Hajeri PB
Drug Discov Today; 2009 Sep; 14(17-18):859-65. PubMed ID: 19540929
[TBL] [Abstract][Full Text] [Related]
16. Small Interfering RNAs and their Delivery Systems: A Novel Powerful Tool for the Potential Treatment of HIV Infections.
Bolhassani A; Milani A
Curr Mol Pharmacol; 2020; 13(3):173-181. PubMed ID: 31760929
[TBL] [Abstract][Full Text] [Related]
17. Molecular design and delivery of siRNA.
Inoue A; Sawata SY; Taira K
J Drug Target; 2006; 14(7):448-55. PubMed ID: 17062391
[TBL] [Abstract][Full Text] [Related]
18. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept.
Chong RH; Gonzalez-Gonzalez E; Lara MF; Speaker TJ; Contag CH; Kaspar RL; Coulman SA; Hargest R; Birchall JC
J Control Release; 2013 Mar; 166(3):211-9. PubMed ID: 23313112
[TBL] [Abstract][Full Text] [Related]
19. Pulmonary delivery of therapeutic siRNA.
Lam JK; Liang W; Chan HK
Adv Drug Deliv Rev; 2012 Jan; 64(1):1-15. PubMed ID: 21356260
[TBL] [Abstract][Full Text] [Related]
20. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
Akhtar S; Benter I
Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
